DrugCite
Search

PENTOSTATIN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Pentostatin Adverse Events Reported to the FDA Over Time

How are Pentostatin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Pentostatin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Pentostatin is flagged as the suspect drug causing the adverse event.

Most Common Pentostatin Adverse Events Reported to the FDA

What are the most common Pentostatin adverse events reported to the FDA?

Neutropenia
30 (2.07%)
Dyspnoea
27 (1.86%)
Diarrhoea
25 (1.73%)
Pyrexia
25 (1.73%)
Nausea
22 (1.52%)
Hypotension
21 (1.45%)
Lymphopenia
18 (1.24%)
Chills
17 (1.17%)
Fatigue
16 (1.1%)
Febrile Neutropenia
16 (1.1%)
Neutrophil Count Decreased
16 (1.1%)
Show More Show More
Pneumonia
16 (1.1%)
Thrombocytopenia
16 (1.1%)
Renal Failure
15 (1.04%)
Sepsis
15 (1.04%)
Vomiting
15 (1.04%)
Anaemia
13 (.9%)
Dehydration
13 (.9%)
General Physical Health Deteriorati...
13 (.9%)
Hypoxia
13 (.9%)
Pleural Effusion
13 (.9%)
Body Temperature Increased
12 (.83%)
Cough
12 (.83%)
Pancytopenia
12 (.83%)
Respiratory Failure
12 (.83%)
Abdominal Pain
11 (.76%)
Platelet Count Decreased
11 (.76%)
Infusion Related Reaction
10 (.69%)
Pulmonary Oedema
10 (.69%)
White Blood Cell Count Decreased
10 (.69%)
Acute Respiratory Distress Syndrome
9 (.62%)
Asthenia
9 (.62%)
Blood Creatinine Increased
9 (.62%)
Fungal Infection
9 (.62%)
Lung Infiltration
9 (.62%)
Confusional State
8 (.55%)
Haemoglobin Decreased
8 (.55%)
Lymphocyte Count Decreased
8 (.55%)
Multi-organ Failure
8 (.55%)
Oedema Peripheral
8 (.55%)
Respiratory Distress
8 (.55%)
Ascites
7 (.48%)
Graft Versus Host Disease
7 (.48%)
Headache
7 (.48%)
Lymphadenopathy
7 (.48%)
Renal Failure Acute
7 (.48%)
Tumour Lysis Syndrome
7 (.48%)
Wheezing
7 (.48%)
Anaemia Haemolytic Autoimmune
6 (.41%)
Aspergillosis
6 (.41%)
Atelectasis
6 (.41%)
Bacteraemia
6 (.41%)
Blood Bilirubin Increased
6 (.41%)
Death
6 (.41%)
Drug Hypersensitivity
6 (.41%)
Immunosuppression
6 (.41%)
Lung Infection
6 (.41%)
Oxygen Saturation Decreased
6 (.41%)
Pulmonary Alveolar Haemorrhage
6 (.41%)
Refusal Of Treatment By Patient
6 (.41%)
Drug Ineffective
5 (.35%)
Lethargy
5 (.35%)
Oedema
5 (.35%)
Oropharyngeal Pain
5 (.35%)
Pneumonia Bacterial
5 (.35%)
Septic Shock
5 (.35%)
Throat Tightness
5 (.35%)
Acute Graft Versus Host Disease In ...
4 (.28%)
Alanine Aminotransferase Increased
4 (.28%)
Aspartate Aminotransferase Increase...
4 (.28%)
Blood Albumin Decreased
4 (.28%)
Blood Calcium Decreased
4 (.28%)
Blood Lactate Dehydrogenase Increas...
4 (.28%)
Blood Sodium Decreased
4 (.28%)
Cardio-respiratory Arrest
4 (.28%)
Chest Discomfort
4 (.28%)
Chest Pain
4 (.28%)
Chronic Lymphocytic Leukaemia
4 (.28%)
Chronic Lymphocytic Leukaemia Recur...
4 (.28%)
Clostridial Infection
4 (.28%)
Condition Aggravated
4 (.28%)
Cytomegalovirus Infection
4 (.28%)
Electromechanical Dissociation
4 (.28%)
Fluid Retention
4 (.28%)
Gastrointestinal Disorder
4 (.28%)
Haemolytic Anaemia
4 (.28%)
Hepatic Cirrhosis
4 (.28%)
Hyponatraemia
4 (.28%)
Infection
4 (.28%)
Lung Disorder
4 (.28%)
Mycobacterium Avium Complex Infecti...
4 (.28%)
Nasopharyngitis
4 (.28%)
Nephropathy Toxic
4 (.28%)
Neutrophil Count Abnormal
4 (.28%)
Pain
4 (.28%)
Pericardial Effusion
4 (.28%)
Pneumonia Necrotising
4 (.28%)
Pneumonia Respiratory Syncytial Vir...
4 (.28%)
Productive Cough
4 (.28%)
Progressive Multifocal Leukoencepha...
4 (.28%)
Pulmonary Embolism
4 (.28%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Pentostatin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Pentostatin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Pentostatin

What are the most common Pentostatin adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Pentostatin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Pentostatin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Pentostatin According to Those Reporting Adverse Events

Why are people taking Pentostatin, according to those reporting adverse events to the FDA?

Chronic Lymphocytic Leukaemia
52
T-cell Prolymphocytic Leukaemia
16
Graft Versus Host Disease
15
Hairy Cell Leukaemia
11
Product Used For Unknown Indication
8
Large Granular Lymphocytosis
5
Show More Show More
Drug Use For Unknown Indication
5
Adult T-cell Lymphoma/leukaemia
4
Non-hodgkins Lymphoma
3
Chronic Graft Versus Host Disease
2
Stem Cell Transplant
2
Non-hodgkins Lymphoma Stage Iv
2
Chemotherapy
2
Prophylaxis Against Graft Versus Ho...
1
Hepatosplenic T-cell Lymphoma
1
Malignant Lymphoid Neoplasm
1
C-reactive Protein Increased
1
B-cell Small Lymphocytic Lymphoma
1
Chimerism
1
B-cell Lymphoma
1
Immunosuppression
1
Leukaemia
1
Asthenia
1
Prolymphocytic Leukaemia
1
T-cell Lymphoma
1
Hodgkins Disease
1
Neoplasm Malignant
1
Lymphocytic Leukaemia
1
Lymphoma
1

Drug Labels

LabelLabelerEffective
PentostatinBedford Laboratories24-MAY-10

Pentostatin Case Reports

What Pentostatin safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Pentostatin. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Pentostatin.